Pixantrone plus rituximab versus gemcitabine plus rituximab in patients with relapsed aggressive B-cell non-Hodgkin lymphoma not eligible for stem cell transplantation: a phase 3, randomized, multicentre trial (PIX306).
Document Type
Article
Publication Date
1-1-2020
Publication Title
British journal of haematology
Abstract
PIX306 was a phase 3, randomised, single-blind, multicentre trial conducted in adult patients with diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL) grade 3 who relapsed after ≥1 rituximab-containing regimen and were not eligible for a stem cell transplant. Patients were randomised 1:1 to pixantrone 50 mg/m
Clinical Institute
Cancer
Department
Oncology
Department
Hematology
Recommended Citation
Pettengell, Ruth; Długosz-Danecka, Monika; Andorsky, David; Belada, David; Georgiev, Pencho; Quick, Donald; Singer, Jack W; Singh, Simran B; Pallis, Athanasios; Egorov, Anton; and Salles, Gilles, "Pixantrone plus rituximab versus gemcitabine plus rituximab in patients with relapsed aggressive B-cell non-Hodgkin lymphoma not eligible for stem cell transplantation: a phase 3, randomized, multicentre trial (PIX306)." (2020). Articles, Abstracts, and Reports. 2606.
https://digitalcommons.providence.org/publications/2606
